TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
13.32 ^USD	-1.11%		-5.53%	-22.01%

29/04	North American Morning Briefing : Investors Brace -2-	DJ
18/04	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT

TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 11, 2022 at 02:02 am IST

TG Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 2.02 million compared to USD 0.793 million a year ago. Net loss was USD 69.01 million compared to USD 90.63 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.69 a year ago.

Latest news about TG Therapeutics, Inc.

North American Morning Briefing : Investors Brace -2-	29/04	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	19/04	MT
Sector Update: Health Care	19/04	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04	CI
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	14/03	MT
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	01/03	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	29/02	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	29/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28/02	MT
Transcript : TG Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28/02	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	26/02	MT
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.	12/02	CI
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	05/02	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	11/01	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	11/01	MT
TG Therapeutics Shares Fall After Reporting Net Product Preliminary Revenues for Briumvi; Provides 2024 Targets	10/01	MT
TG Therapeutics Reports Net Product Preliminary Q4 and 2023 US Revenue for Briumvi; Provides 2024 Targets	10/01	MT
Looming Big Bank Earnings, Inflation Data Fuel Cautiousness, Driving Muted Premarket Action for US Equity Futures	10/01	MT
Transcript : TG Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	10/01
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	09/01	MT

Chart TG Therapeutics, Inc.

Duration

Period

More charts

Company Profile

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Sector

Biotechnology & Medical Research

Calendar

08/05/2024 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for TG Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.32 USD

Average target price

29.75 USD

Spread / Average Target

+123.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TG THERAPEUTICS, INC.	-22.01%	1.93B
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+45.66%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research